| 赵 涵,张坚生,陈志敏.艾滋病相关非霍奇金淋巴瘤38例治疗及预后分析[J].肿瘤学杂志,2020,26(10):902-906. |
| 艾滋病相关非霍奇金淋巴瘤38例治疗及预后分析 |
| Treatment and Prognosis of AIDS Patients with Non-Hodgkin Lymphoma：An Analysis of 38 Cases |
| 投稿时间：2020-02-04 |
| DOI：10.11735/j.issn.1671-170X.2020.10.B010 |
|
 |
| 中文关键词: 艾滋病 非霍奇金淋巴瘤 化疗 预后 |
| 英文关键词:AIDS non-hodgkin's lymphoma chemotherapy prognosis |
| 基金项目:“十三五”国家科技重大专项（2017ZX10202102-004-001）；广东省自然科学基金（2016A030310108） |
|
| 摘要点击次数: 808 |
| 全文下载次数: 193 |
| 中文摘要: |
| 摘 要：［目的］ 探讨艾滋病相关非霍奇金淋巴瘤的临床特点、预后。［方法］ 38例化疗疗程大于2程，随访日期大于1年及以上的艾滋病合并非霍奇金淋巴瘤患者入组，分析患者的治疗方法及预后情况。［结果］ 38例中有30例患者在化疗期间出现Ⅲ~Ⅳ度骨髓抑制，只有8例患者按原定化疗剂量完成化疗，有6例患者因化疗相关毒副作用使用分段化疗(CR率类似)且OS及EFS、OS率无明显差异。5例在化疗期间仍使用NNRTIs与PIs行HAART治疗的患者均出现反复的IV度骨髓抑制及肝功能损害。38例患者中有16例CR，4例CRu，10例PR，3例SD，5例PD。38例患者生存期最长47个月，最短3个月，中位生存时间16个月。［结论］ 艾滋病相关非霍奇金淋巴瘤患者普通化疗方案耐受度差，且抗感染治疗及抗病毒治疗与化疗药物间有明显相互作用，使用整合酶抑制剂和分段化疗可提高患者的耐受度和缓解率。 |
| 英文摘要: |
| Abstract：［Objective］To investigate the clinical features and prognosis of AIDS patients with non-Hodgkin lymphoma. ［Methods］ Thirty-eight AIDS patients with non-Hodgkin's lymphoma，who had received more than 2 cycle of chemotherapy and at least one year of followed-up were enrolled，the treatment and prognosis of patients were analyzed.［Results］ Among all recruited patients，30 cases showed Ⅲ~Ⅳ degree myelosuppression during chemotherapy，and only 8 patients completed full-dose chemotherapy. Six patients received section chemotherapy because of side effects related to the chemotherapy；they had similar CR rate，and had no significant differences in OS，EFS and OS rate，compared with those in patients completing full-dose chemotherapy. Five patients who continued to receive HAART including NNRTIs and PIs during chemotherapy，had repeated Ⅳ degree myelosuppression and liver function damage. There were 16 CR，4 CRu，10 PR，3 SD and 5 PD in all 38 patients. The survival time ranged from 3 to 47 months with a median survival time of 16 months. ［Conclusion］ The tolerance of chemotherapy regimens is poor in AIDS patients with non-Hodgkin's lymphoma. Considering significant interactions between anti-infection drug，antiviral drug and chemotherapy drugs，combination of the integrase inhibitors and staging chemotherapy may improve the patient's tolerance and remission rate. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |